Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis.

Marie EvansHannah BowerElinor CockburnStefan H JacobsonPeter BaranyJuan-Jesus Carrero

Published in: Clinical kidney journal (2020)

Anaemia remains highly prevalent in advanced CKD. Patients with anaemia received moderate ESA doses with a relatively low prevalence of iron use. Higher doses of ESA were associated with inflammation and a higher risk of MACE.

Keyphrases

iron deficiency
chronic kidney disease
end stage renal disease
oxidative stress
risk factors
high intensity
cross sectional
recombinant human